Efficacy of Weflow Embedded Branch Stents in the Treatment of Stanford Type B Dissection Involving Left Subclavian Artery.

OBJECTIVE

Weflow embedded branch stent was used in the treatment of Stanford type B aortic dissection (TBAD) involving the left subclavian artery (LSA), and the effectiveness of the stent in the short and medium and term was observed.

METHODS

The clinical data of 22 patients with TBAD involving LSA treated with Weflow embedded branch stent from the First Hospital of Hebei Medical University from December 2020 to October 2021were retrospectively analyzed. The changes in systolic blood pressure of the left upper limb at the onset and postoperative period, the patency rate of left subclavian artery stent at 1, 6, and 12 months after surgery, the change of true and false lumen diameters, and the occurrence of complications were evaluated.

RESULTS

The patency rate of the left subclavian artery (LSA) branch stent was 100% at 1 month, 6 months, and 12 months after surgery. With the extension of postoperative time, the diameter of the aortic true lumen gradually increased. One month after surgery, the remodeling indexes of the aorta were improved, and with the extension of postoperative time, the diameter of the aortic false lumen decreased gradually. In the perioperative period, 1 case of vision, 1 case of insomnia, 1 case of retrograde type A dissection, 2 cases of type Ia endoleak, and no other new complications. During the follow-up, 2 patients with disappeared endoleak and 1 patient with retrograde dissection was in good condition after treatment.

CONCLUSIONS

1. Weflow embedded branch stent has good safety and reliability in the treatment of TBAD; 2. When LSA is involved, it can effectively improve the blood pressure of the patient's left upper limb, and the patency rate of the branch stent is good within 1 year; 3. Weflow embedded branch stent has a good short-term effect in aortic remodeling, and the medium- and long-term effect needs to be evaluated; 4. Weflow embedded branch stent had no obvious complications during the 1-year follow-up.